Overview and capabilities of Naobios
Naobios provides bioprocess development and contract manufacturing services for viral vaccines and viral vectors. The company was acquired by Clean Biologics on March 1st, 2019 and now supports clients for process development and the manufacture of preclinical and clinical batches.
In the newsSee all news
Bioprocess development webinar
Tackling challenges in Development and scale-up of Virus and Vaccine Manufacturing Processes using microcarriers.
Save the date, our next webinar will take place on April 15th! Join Luís Raiado and Juliette Ambrosini next month for a brand-new edition tackling challenges posed by microcarrier-based processes in bioprocess development and scale-up.
New in the lab
New Bioreactors on Process Development – Increasing flexibility and capacity
To continuously improve Process Development, Naobios acquired three new bioreactor control systems which increase flexibility and capacity and rely on independent monitoring and control of vessels up to 40 L.
BSL3 manufacturing area
Naobios opens a new BioSafety Level 3 manufacturing unit
Naobios is pleased to announce the opening of a new 110m2 BSL3 manufacturing area, following major revamping of the facility.
Clean Biologics was born in 2018 from a fruitful alliance between Clean Cells and Archimed. Through this partnership, the group soon acquired and integrated CDMO Naobios to extend the service offer and to promote our future-oriented thinking. The expertise, transparency, progress and a human-centred view are at the core of our identity. Day after day, we use our knowledge and our skills to deliver high-quality services in innovative projects with an unwavering dynamism and commitment.
Over 15 Years
History in GMP and Process Development Activities
of 40 people